Correction to: British Journal of Cancer (2014) 110, 894–898; doi:10.1038/bjc.2013.811; published online 7 January 2014
After publication of the above paper in the British Journal of Cancer, a discrepancy was found in the text. The Results section contains the following: ‘As a representative of this class of TKIs, sorafenib was further evaluated and found to also potently inhibit the OATP1B1-mediated transport of docetaxel with a half-inhibitory maximum concentration of 6.96 nM (Figure 1B)...’ However, Figure 1B reports the concentration as 69.6 nM.
The authors would like to apologise for this error. The correct concentration is 6.96 nM.